Partial protective immunity against infection with Trypanosoma cruzi can be induced in experimental animals as judged by a reduction in mortality, a delay in the time of appearance of parasites, a reduction in the incidence of parasitemia, or a reduction in parasite levels. Immunization protocols have included the use of live attenuated parasites (2, 10, 17) , inactivated parasites (7, 14, 15) , fractionated parasite material (5, 12) , and a glycoprotein fraction (23) . The fact that antibodies play an important role in protection (8, 9, 13, 22, 26) offers the possibility of developing a vaccine containing only those antigens that induce protective antibodies but do not induce an autoimmune response that causes the pathology of chronic Chagas' disease (19, 27) .
Protective antigens can be identified by either purifying individual antigens and determining which induce protective immunity or inducing protective immunity with crude antigen preparations and determining the specificity of the antibody species that are induced by them. The information obtained from the second approach can then be used to select specific antigens for purification and subsequent protection studies.
In this study, the second approach was used to show that the induction of partial protection after immunization with inactivated trypomastigotes correlated with the presence of antibodies that reacted with a limited number of trypomastigote-specific antigens.
MATERIALS AND METHODS
Growth of T. cruzi. T. cruzi MERC 2D14 was derived from the Y strain isolated by Silva and Nussenzweig (24) and cloned by intraperitoneal inoculation of single organisms into mice (21) .
Epimastigotes were grown at 27°C to a density of 2 x 107 per ml in liver infusion-tryptose medium (4, 6) Trypomastigotes were grown in irradiated myoblast cell cultures (21) . At the time when intracellular amastigotes were transforming into trypomastigotes (ca. 4 days after infection), the culture supernatant was replaced with fresh medium. The medium was collected 24 h later, and trypomastigotes were separated from the host cell debris by passage through a DEAE-cellulose column (20) , centrifuged at 1,700 x g for 10 min, and suspended in PBS plus phenylmethylsulfonyl fluoride (10-4 M (3, 18, 25) . After transfer, the paper was rinsed three times for 10 min with 100 ml of PNEA buffer (0.01 M phosphate buffer, 0.14 M NaCl, 0.002 M EDTA, 0.02% NaN3 [pH 7.1]). The paper was then placed for 4 h at 37°C in a sealed plastic bag with 60 ml of PNEA buffer containing 0.5% gelatin to block the remaining protein-reactive sites, followed by three washes (15 min each) with 60 ml of TEN buffer (0.15 M Tris, 0.15 M NaCl, 0.005 M EDTA, 0.02% NaN3 [pH 7.4]) containing 0.05% Triton X-100 and 0.25% gelatin. The paper was cut lengthwise into 0.5-cm strips, and each strip was placed in a 50-ml screwcapped round-bottom glass tube with 2 ml of TEN buffer and 20 ,ul of the appropriate serum. After gentle rocking at 22°C
for 16 h, the paper strips were washed three times for 15 min with 10 ml of TEN buffer. Each strip was then incubated for 16 h with gentle rocking in 2 ml of TEN buffer containing 2 x 106 cpm of 125I-labeled protein A, after which the strips were washed three times (30 min each) with 10 ml of high salt-sarcosinate buffer (0.05 M Tris, 1.0 M NaCl, 0.005 M EDTA, 0.25% gelatin, 0.4% sodium-N-lauroyl sarcosinate, 0.02% NaN3 [pH 7.4]) and twice (15 min each) with 10 ml of TEN buffer. After drying at room temperature, the strips were mounted on paper with the strip containing the 14C-labeled marker proteins and exposed to X-ray film (XAR-5; Eastman Kodak Co., Rochester, N.Y. disease. Therefore, a resistant strain of mice was infected with a low dose of trypomastigotes which resulted in chronic infections (parasites were observed in the blood more than 3 months after infection), low levels of parasites in the blood during the early phase of the disease, and negligible mortality rates. The number of parasites in the blood was too low for quantitation, and immunizations were evaluated for their ability to prevent parasitemia in CF1 mice after infection with T. cruzi trypomastigotes. A number of immunization schedules were tested, and it was found that repeated immunization with increasing doses of irradiated trypomastigotes resulted in partial protection. immunized mice at a frequency not significantly different from that in nonimmunized animals, whereas parasites appeared in fewer trypomastigote-immunized mice and their appearance was delayed significantly.
Characterization of parasite-specific antibodies in immunized mice. Antibody species in sera from immunized mice were studied in Western blot analyses for their reactivity with individual epimastigote, trypomastigote, and amastigote polypeptides. These sera, from three mice in each group described in Fig. 1A , were collected and pooled 14 days after the final immunization with epimastigotes or trypomastigotes. In addition, pooled sera from three control (nonimmunized and noninfected) CF1 mice was used; pooled sera taken from three T. cruzi-infected but nonimmunized CF1 mice at 15 weeks after infection were also used.
The distribution of antibodies against epimastigote polypeptides is shown in Fig. 2A . Nonimmunized infected mice developed antibodies that reacted with a large number of epimastigote polypeptides, whereas sera from mice immunized with irradiated epimastigotes contained a single major antibody species that was directed against a 57,000-D epimastigote polypeptide. Sera from trypomastigote-immunized mice did not contain antibodies that reacted with epimastigote polypeptides. A few weakly reactive antibody species were present in control sera, but their presence was probably due to nonspecific reactions.
A large number of antibody species that reacted with trypomastigote polypeptides ranging from 20,000 to more than 100,000 D were present in nonimmunized T. cruzi-infected mice, and few weakly reactive antibody species were observed in the sera of control mice (Fig. 2B) . Trypomastigote-specific antibodies were not observed in sera from mice that were immunized with irradiated epimastigotes, but three or possibly four species were detected in sera from trypomastigote-immunized mice. The major antibody species was directed against a 100,000-D polypeptide, and minor species were directed against two or three polypeptides larger than 200,000 D.
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> trypomastigote-immunized mice did not contain amastigotespecific antibodies (Fig. 2C) . To ascertain that the reactive polypeptides were not derived from myoblast cells in which trypomastigotes and amastigotes had been grown, it was established that none of the sera reacted with polypeptides from uninfected myoblast cells (data not shown). DISCUSSION A number of T. cruzi parasite preparations were evaluated for their ability to induce protective immunity in mice. Parasites were observed in the blood of nonimmunized mice ca. 2 weeks after infection and remained for several months without significant mortality rates. The parasite load was too low for quantitation; therefore, protection was evaluated by scoring the percentage of parasitemia-positive mice at various times after infection. Partial protection was observed when mice were immunized with increasing doses of irradiated trypomastigotes at weekly intervals. In a typical experiment (Fig. 1) , these doses were 105, 106, 101, and 2 x 107 organisms per mouse. Epimastigotes never induced protection, and results with amastigotes (data not shown) were variable in that limited protection was observed occasionally. It should be emphasized that complete protection after immunization with irradiated trypomastigotes was never observed. Rather, the appearance of parasites was delayed, and some animals appeared to remain parasite free throughout the course of the experiment.
Parasites in the blood of infected animals were detected by microscopic observations, but too few parasites were present under our experimental conditions to allow for quantitation. However, infection of control or epimastigote-immunized mice with T. cruzi resulted in the appearance of trypomastigotes in blood at sufficiently high numbers that they could be observed microscopically after viewing fewer than three fields. On the other hand, it generally took 10 fields or more to observe parasites in positive blood from infected mice after immunization with trypomastigotes. Mice that did not show blood parasitemia after at least 20 fields were viewed were considered parasitemia negative. In follow-up experiments, blood samples from parasitemia-positive and -nega- (Fig. 1A) with polypeptides derived from epimastigotes, trypomastigotes, and amastigotes. The following controls were included: C, pooled sera from three uninfected, nonimmunized mice; I, pooled sera from three nonimmunized miceobtained 15 The objective of this work was to define antibody species in the sera of partially immune mice with regard to their reactivity with parasite antigens. In our analyses, the complex polypeptide mixture of each of the parasite stages was separated into individual polypeptides by electrophoresis in sodium dodecyl sulfate-polyacrylamide gels, followed by transfer to nitrocellulose paper in the same relative positions in which they were present in the gel. Antibodies that bound to individual polypeptides were visualized with 125I-labeled staphylococcal protein A and autoradiography. This probe reacts only with murine immunoglobulin G, which is the immunoglobulin class mostly responsible for protection (26) . In other experiments it was found that a more general probe, 125I-labeled goat anti-mouse immunoglobulin, gave identical results. This system requires an efficient transfer of all parasite antigens from the gels to the nitrocellulose paper. Experiments in which gels and nitrocellular paper were stained before and after transfer showed that this was indeed the case (data not shown).
A large number of parasite-specific antibodies are generated after infection of CF1 mice with T. cruzi (Fig. 2) . Some of the reactive antigens may be similar to the 85,000-to 100,000-D antigens described previously (1, 16) . Since infection with live T. cruzi protects mice against superinfection (2, 10, 17) , it seems likely that some of these antibody species are involved in protective immunity; however, the total number of antibodies in these sera is too large to be of analytical value.
Partial protection after immunization with irradiated trypomastigotes correlated with the presence of antibodies against a 100,000-D antigen that was present in extracts of trypomastigotes but not in those of epimastigotes or amastigotes. As such, it differs from the 90,000-D polypeptide described by Scott and Snary (23) that is present in all intermediate stages of T. cruzi and that will induce protective immunity or the 90,000-D trypomastigote and amastigote surface glycoprotein described by Nogueira et al. (16) . It may be similar to a 100,000-D polypeptide at the surface of metacyclic polypeptides (28) .
The possibility of this class of antibodies being involved in protective immunity is strengthened by the observation that antibodies against the 100,000-D trypomastigote polypeptide were also present in the sera of nonimmunized infected mice. (Superinfection of these mice after they have become parasitemia negative generally does not result in the reappearance of parasites in their blood.) Immunization with irradiated trypomastigotes also induced antibodies against trypomastigote-specific polypeptides greater than 200,000 D. These may be similar to those described by Zingales et al. (29) .
The use of an irradiated myoblast culture system (21) has made it possible to obtain trypomastigotes in significant yields such that the 100,000-D polypeptide can be isolated and tested for its ability to induce protective immunity. Unfortunately, as judged from stained sodium dodecyl sulfate-polyacrylamide gels, this polypeptide appears to be a minor constituent of trypomastigotes. If its utility as a protective antigen has been established, it may require the application of recombinant DNA technology to obtain sufficient quantities for vaccine preparation.
